Cancer survivor experiencing fatigue
Conditions
Interventions
Group 1: Intermittent Hypoxia-Hyperoxia Training (IHHT)
The intervention consists of two sessions per week, each lasting 45 minutes. Each session comprises 6–8 cycles of alternating oxygen concentrati
Sponsors
Universitätsklinikum Hamburg - Eppendorf
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - Cancer survivors defined as (hemato-)oncological patients in follow-up care = 6 months after completion of tumor-directed therapy* with no evidence of disease recurrence. (*Ongoing antihormonal therapy (aromatase inhibitors, tamoxifen) or CDK4/6 inhibitors are not excluded.) - Fatigue score = 4 on a numerical rating scale (NRS, 0–10). - Age = 18 years. - Access to the internet as well as a PC, laptop, or tablet. - Proficiency in the German language (written and spoken). - Willingness to participate in an IHHT study / signed informed consent. - ECOG Performance Status 0–2.
Exclusion criteria
Exclusion criteria: - History of hypoxia intolerance. - Resting hypoxemia (SpO2 <90%). - Anemia = CTCAE Grade 1 (<10 g/dL) or blood transfusion within the last four weeks. - Sickle cell anemia. - Inadequately controlled diabetes mellitus. - Known, unstable thyroid disease, particularly hypothyroidism. - Instable coronary heart disease. - Uncontrolled cardiac arrhythmia. - Uncontrolled arterial hypertension. - Recent myocardial infarction or stroke (<3 months). - Aortocoronary bypass surgery (CABG) (<3 months). - Epilepsy or other seizure disorders. - Severe migraine with aura. - Increased intracranial pressure. - Advanced non-oncological chronic diseases: Child-Pugh Class C liver cirrhosis, end-stage renal disease, heart failure (NYHA III or IV). - Pregnancy. - Previous participation in similar interventions or established active IHHT practice. - Cognitive or linguistic barriers impairing the performance of the interventions. - Other diseases or conditions that, in the investigator’s opinion, jeopardize patient safety or the feasibility of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in Brief Fatigue Inventory (BFI) score from baseline (T0) to post-intervention (T1) | — |
Secondary
| Measure | Time frame |
|---|---|
| - MFI-20 - EORTC QLQ-C30 - PHQ-9 - GAD-7 - PSQI - FitMáx© questionnaire - Functional status / clinical functional tests -- Heart rate variability (HRV) measured by TUR CellOxy® -- 6-minute walk test (6MWT) -- Handgrip strength measured by dynamometer - Qualitative evaluation | — |
Countries
Germany
Contacts
Public ContactAlina Busch
Universitätsklinikum Hamburg - Eppendorf
Outcome results
None listed